APA (7th ed.) Citation

A, D., T, P., A, B., J, M., SJ, S., T, F., . . . JL, L. (2023). Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clinical cancer research : an official journal of the American Association for Cancer Research, 29(21), 4373. https://doi.org/10.1158/1078-0432.CCR-23-0798

Chicago Style (17th ed.) Citation

A, Drakaki, et al. "Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab Versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29, no. 21 (2023): 4373. https://doi.org/10.1158/1078-0432.CCR-23-0798.

MLA (9th ed.) Citation

A, Drakaki, et al. "Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab Versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 21, 2023, p. 4373, https://doi.org/10.1158/1078-0432.CCR-23-0798.